Using circulating tumor cells to inform on prostate cancer biology and clinical utility

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin 2014;64:9–29
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147–54
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995–2005
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411–22
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213–23
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187–97
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371:1028–38
   PubMed Web of Science ®Google Scholar
• Loriot Y, Bianchini D, Ileana E,et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013;24:1807–12
   PubMed Web of Science ®Google Scholar
• Noonan KL, North S, Bitting RL, et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013;24:1802–7
   PubMed Web of Science ®Google Scholar
• Schrader AJ, Boegemann M, Ohlmann CH, et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014;65:30–6
   PubMed Web of Science ®Google Scholar
• Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11–22
   PubMed Web of Science ®Google Scholar
• Arora VK, Schenkein E, Murali R, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013;155:1309–22
   PubMed Web of Science ®Google Scholar
• Thadani-Mulero M, Portella L, Sun S, et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res 2014;74:2270–82
   PubMed Web of Science ®Google Scholar
• Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897–904
   PubMed Web of Science ®Google Scholar
• Arya M, Bott SR, Shergill IS, et al. The metastatic cascade in prostate cancer. Surg Oncol 2006;15:117–28
   PubMed Web of Science ®Google Scholar
• Muller V, Stahmann N, Riethdorf S, et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005;11:3678–85
   PubMed Web of Science ®Google Scholar
• Attard G, Swennenhuis JF, Olmos D, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009;69:2912–18
   PubMed Web of Science ®Google Scholar
• Darshan MS, Loftus MS, Thadani-Mulero M, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011;71:6019–29
   PubMed Web of Science ®Google Scholar
• Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368:1199–209
   PubMed Web of Science ®Google Scholar
• Friedlander TW, Ngo VT, Dong H, et al. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. Int J Cancer 2014;134:2284–93
   PubMed Web of Science ®Google Scholar
• Heitzer E, Auer M, Gasch C, et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res 2013;73:2965–75
   PubMed Web of Science ®Google Scholar
• Jiang Y, Palma JF, Agus DB, et al. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem 2010;56:1492–5
   PubMed Web of Science ®Google Scholar
• Lohr JG, Adalsteinsson VA, Cibulskis K, et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol 2014;32:479–84
   PubMed Web of Science ®Google Scholar
• Magbanua MJM, Sosa EV, Scott JH, et al. Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer 2012;12:78
   PubMed Web of Science ®Google Scholar
• Stott SL, Hsu CH, Tsukrov DI, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci USA 2010;107:18392–7
   PubMed Web of Science ®Google Scholar
• Yu M, Sting DT, Stott SL, et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 2012;487:510–13
   PubMed Web of Science ®Google Scholar
• Bidard FC, Fehm T, Ignatiadis M, et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev 2013;32:179–88
   PubMed Web of Science ®Google Scholar
• Wind J, Tuynman JB, Tibbe AG, et al. Circulating tumour cells during laparoscopic and open surgery for primary colonic cancer in portal and peripheral blood. Eur J Surg Oncol 2009;35:942–50
   PubMed Web of Science ®Google Scholar
• de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302–9
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Eisenberger MA, Halabi S, et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol 2012;61:549–59
   PubMed Web of Science ®Google Scholar
• Miyamoto DT, Sequist LV, Lee RJ. Circulating tumour cells-monitoring treatment response in prostate cancer. Nat Rev Clin Oncol 2014;11:401–12
   PubMed Web of Science ®Google Scholar
• Bitting RL, Boominathan R, Rao C, et al. Development of a method to isolate circulating tumor cells using mesenchymal-based capture. Methods 2013;64:129–36
   PubMed Web of Science ®Google Scholar
• Mani SA, Guo W, Liao MJ, et al. The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704–15
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Marengo MS, Oltean S, et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 2011;9:997–1007
   PubMed Web of Science ®Google Scholar
• Casavant BP, Guckenberger DJ, Berry SM, et al. The VerIFAST: an integrated method for cell isolation and extracellular/intracellular staining. Lab Chip 2013;13:391–6
   PubMed Web of Science ®Google Scholar
• Saucedo-Zeni N, Mewes S, Niestroj R, et al. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol 2012;41:1241–50
   PubMed Web of Science ®Google Scholar
• Talasaz AH, Powell AA, Huber DE, et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci USA 2009;106:3970–5
   PubMed Web of Science ®Google Scholar
• Todenhofer T, Hennenlotter J, Feyerabend S, et al. Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients. Anticancer Res 2012;32:3507–13
   PubMed Web of Science ®Google Scholar
• Müller V, Riethdorf S, Rack B, et al. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res 2012;14:R118
   PubMed Web of Science ®Google Scholar
• Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007;450:1235–9
   PubMed Web of Science ®Google Scholar
• Ozkumur E, Shah AM, Ciciliano JC, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med 2013;5:179ra47
   PubMed Web of Science ®Google Scholar
• Lu YT, Zhao L, Shen Q, et al. NanoVelcro Chip for CTC enumeration in prostate cancer patients. Methods 2013;64:144–52
   PubMed Web of Science ®Google Scholar
• Winer-Jones JP, Vahidi B. Circulating tumor cells: clinically relevant molecular access based on a novel CTC flow cell. PLoS One 2014;9:e86717
   PubMed Web of Science ®Google Scholar
• Krishnamurthy S, Bischoff F, Ann Mayer J, et al. Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer. Cancer Med 2013;2:226–33
   Google Scholar
• Kirby BJ, Jodari M, Loftus MS, et al. Functional characterization of circulating tumor cells with prostate-cancer-specific microfluidic device. PLoS One 2012;7:e35976
   PubMed Web of Science ®Google Scholar
• Saliba AE, Saias L, Psychari E, et al. Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays. Proc Natl Acad Sci USA 2010;107:14524–9
   PubMed Web of Science ®Google Scholar
• Casavant BP, Mosher R, Warrick JW, et al. A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells. Methods 2013;64:137–43
   PubMed Web of Science ®Google Scholar
• Ramirez JM, Fehm T, Orsini M, et al. Prognostic relevance of viable circulating tumor cells detected by EPISPOT in metastatic breast cancer patients. Clin Chem 2014;60:214–21
   PubMed Web of Science ®Google Scholar
• Hsieh HB, Marrinucci D, Bethel K, et al. High speed detection of circulating tumor cells. Biosens Bioelectron 2006;21:1893–9
   PubMed Web of Science ®Google Scholar
• Harb W, Fan A, Tran T, et al. Mutational analysis of circulating tumor cells using a novel microfluidic collection device and qPCR assay. Transl Oncol 2013;6:528–38
   PubMed Web of Science ®Google Scholar
• Paris PL, Kobayashi Y, Zhao Q, et al. Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer. Cancer Lett 2009;277:164–73
   PubMed Web of Science ®Google Scholar
• Lu J, Fan T, Zhao Q, et al. Isolation phenotype from breast cancer patients. Int J Cancer 2010; 126:669–83
   PubMed Web of Science ®Google Scholar
• Alix-Panabieres C, Rebillard X, Brouillet JP, et al. Detection of circulating prostate-specific antigen-secreting cells in prostate cancer patients. Clin Chem 2005;51:1538–41
   PubMed Web of Science ®Google Scholar
• Phillips JA, Xu Y, Xia Z, et al. Enrichment of cancer cells using aptamers immobilized on a microfluidic channel. Anal Chem 2009;81:1033–9
   PubMed Web of Science ®Google Scholar
• Rosenberg R, Gertler R, Friederichs J, et al. Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. Cytometry 2003;49:150–8
   Google Scholar
• Vona G, Sabile A, Louha M, et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. The Am J Pathol 2000;156:57–63
   PubMed Web of Science ®Google Scholar
• Warkiani ME, Guan G, Luan KB, et al. Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells. Lab Chip 2014;14:128–37
   PubMed Web of Science ®Google Scholar
• Islam M, Asghar W, Kim Y, et al. Cell elasticity-based microfluidic label-free isolation of metastatic tumor cells. Br J Med Med Res 2014;4:2129–40
   Google Scholar
• Bobek V, Gurlich R, Eliasova P, Kolostova K. Circulating tumor cells in pancreatic cancer patients: enrichment and cultivation. World J Gastroenterol 2014;20:17163–70
   PubMed Web of Science ®Google Scholar
• Adebayo Awe J, Xu MC, Wechsler J, et al. Three-dimensional telomeric analysis of isolated circulating tumor cells (CTCs) defines CTC subpopulations.Transl Oncol 2013;6:51–65
   PubMed Web of Science ®Google Scholar
• Barradas AM, Terstappen LW. Towards the biological understanding of CTC: capture technologies, definitions and potential to create metastasis. Cancers (Basel) 2013;5:1619–42
   PubMedGoogle Scholar
• Gupta V, Jafferji I, Garza M, et al. ApoStream™, a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood. Biomicrofluidics 2012;6:24133
   PubMed Web of Science ®Google Scholar
• Peeters DJ, De Laere B, Van den Eynden GG, et al. Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from Cell Search enriched blood samples using dielectrophoretic cell sorting. Br J Cancer 2013;108:1358–67
   PubMed Web of Science ®Google Scholar
• Weight RM, Dale PS, Viator JA. Detection of circulating melanoma cells in human blood using photoacoustic flowmetry. Conf Proc IEEE Eng Med Biol Soc 2009;2009:106–9
   PubMedGoogle Scholar
• Ligthart ST, Coumans FA, Attard G, et al. Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival. PLoS One 2011;6:e27419
   Google Scholar
• Sieuwerts AM, Kraan J, Bolt J, et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009;101:61–6
   PubMed Web of Science ®Google Scholar
• Sugimachi K, Yokobori T, Iinuma H, et al. Aberrant expression of plastin-3 via copy number gain induces the epithelial-mesenchymal transition in circulating colorectal cancer cells. Ann Surg Oncol 2013;21:3680–90
   PubMed Web of Science ®Google Scholar
• Yokobori T, Iinuma H, Shimamura T, et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res 2013;73:2059–69
   PubMed Web of Science ®Google Scholar
• Satelli A, Mitra A, Brownlee Z, et al. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res 2015;21:899–906
   PubMed Web of Science ®Google Scholar
• Ameri K, Luong R, Zhang H, et al. Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype. Br J Cancer 2010;102:561–9
   PubMed Web of Science ®Google Scholar
• Theil G, Fischer K, Krahn T, et al. Clinical validation of a medical device for in vivo isolation of circulating tumor cells in prostate cancer patients: one-year follow-up. J Clin Oncol 2014;32:abstr e16027
   Google Scholar
• Stott SL, Lee RJ, Nagrath S, et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2010;2:25ra23
   PubMed Web of Science ®Google Scholar
• Karabacak NM, Spuhler PS, Fachin F, et al. Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc 2014;9:694–710
   PubMed Web of Science ®Google Scholar
• Diamond E, Lee GY, Akhtar NH, et al. Isolation and characterization of circulating tumor cells in prostate cancer. Front Oncol 2012;2:131--58
   Google Scholar
• Alix-Panabieres C, Vendrell JP, Pellé O, et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 2007;53:537–9
   PubMed Web of Science ®Google Scholar
• Friedlander TW, Ngo VT, Dong H, et al. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. Int J Cancer 2014;134:2284–93
   PubMed Web of Science ®Google Scholar
• Vorhies JS, Nemunaitis JJ. Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics. Biologics 2007;1:367–76
   PubMedGoogle Scholar
• Dharmasiri U, Balamurugan S, Adams AA, et al. Highly efficient capture and enumeration of low abundance prostate cancer cells using prostate-specific membrane antigen aptamers immobilized to a polymeric microfluidic device. Electrophoresis 2009;30:3289–300
   PubMed Web of Science ®Google Scholar
• Shibata K, Mori M, Kitano S, Akiyoshi T. Detection of ras gene mutations in peripheral blood of carcinoma patients using CD45 immunomagnetic separation and nested mutant allele specific amplification. Int J Oncol 1998;12:1333–8
   PubMed Web of Science ®Google Scholar
• Yang L, Lang JC, Balasubramanian P, et al. Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells. Biotechnol Bioeng 2009;102:521–34
   PubMed Web of Science ®Google Scholar
• Ferraldeschi R, Krupa R, Louw J, et al. Sequential monitoring and characterization of circulating tumor cells (CTCs) using the epic sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with recently approved therapeutics. J Clin Oncol 2014;32:abstr 78
   Google Scholar
• Lazar DC, Cho EH, Luttgen MS, et al. Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate-tumor-derived LNCaP cell line. Phys Biol 2012;9:016002
   Web of Science ®Google Scholar
• Farace F, Massard C, Vimond N, et al. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer 2011;105:847–53
   PubMed Web of Science ®Google Scholar
• Kolostova K, Broul M, Schraml J, et al. Circulating tumor cells in localized prostate cancer: isolation, cultivation in vitro and relationship to T-stage and Gleason score. Anticancer Res 2014;34:3641–6
   PubMed Web of Science ®Google Scholar
• Poklepovic AS, Wan W, Wu W, et al. ApoStream, an antibody-independent platform, compared to CellSearch for enumeration of circulating tumor cells (CTCs) in patients with metastatic prostate cancer. J Clin Oncol 2012;30:abstr e21058
   Google Scholar
• Fabbri F, Carloni S, Zoli W, et al. Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. Cancer Lett 2013;335:225–31
   PubMed Web of Science ®Google Scholar
• Johnson LM, Gao L, Shields IV, et al. Elastomeric microparticles for acoustic mediated bioseparations. J Nanobiotechnology 2013; 11:22--30
   PubMed Web of Science ®Google Scholar
• Basu S, Campbell HM, Dittel BN, Ray A. Purification of specific cell population by fluorescence activated cell sorting (FACS). J Vis Exp 2010;41:1546--2242
   PubMedGoogle Scholar
• Smith BM, Slade MJ, English J, et al. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J Clin Oncol 2000;18:1432–9
   PubMed Web of Science ®Google Scholar
• Ntouroupi TG, Ashraf SQ, McGregor SB, et al. Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope. Br J Cancer 2008;99:789–95
   PubMed Web of Science ®Google Scholar
• Fizazi K, Morat L, Chauveinc L, et al. High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. Ann Oncol 2007;18:518–21
   PubMed Web of Science ®Google Scholar
• Danila DC, Anand A, Sung CC, et al. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration resistant prostate cancer patients treated with abiraterone acetate. Eur Urol 2011;60:897–904
   PubMed Web of Science ®Google Scholar
• Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, et al. Changes in cytoskeletal protein composition indicative of an epithelial–mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 2005;11:8006–14
   PubMed Web of Science ®Google Scholar
• Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch-and hedgehog-dependent tumor-initiating cells. Cancer Cell 2012;22:373–88
   PubMed Web of Science ®Google Scholar
• Miyamoto DT, Lee RJ, Stott SL, et al. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov 2012;2:995–1003
   PubMed Web of Science ®Google Scholar
• Blackburn EH. Telomere states and cell fates. Nature 2000;408:53–6
   PubMed Web of Science ®Google Scholar
• Ito H, Inoue H, Sando N, et al. Prognostic impact of detecting viable circulating tumour cells in gastric cancer patients using a telomerase-specific viral agent: a prospective study. BMC Cancer 2012;12:346
   PubMed Web of Science ®Google Scholar
• Kim SJ, Masago A, Tamaki Y, et al. A novel approach using telomerase-specific replication-selective adenovirus for detection of circulating tumor cells in breast cancer patients. Breast Cancer Res Treat 2011;128:765–73
   Google Scholar
• Goldkorn A, Vogelzang NJ, Fink LM, et al. Circulating tumor cell (CTC) counts and CTC telomerase activity (TA) as prognostic markers of overall survival (OS) in SWOG S0421: docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer (mCRPC). Markers in cancer. Joint Meeting of the American Society of Clinical Oncology (ASCO), European Organization for Research and Treatment of Cancer (EORTC) and the National Cancer Institute (NCI), Hollywood, FL, USA; 2012
   Google Scholar
• Baccelli I, Schneeweiss A, Riethdorf S, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013;31:539–44
   PubMed Web of Science ®Google Scholar
• Berx G, van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol 2009;1:a003129
   PubMed Web of Science ®Google Scholar
• Lau WM, Teng E, Chong HS, et al. CD44v8-10 is a cancer-specific marker for gastric cancer stem cells. Cancer Res 2014;74:2630–41
   PubMed Web of Science ®Google Scholar
• Satelli A, Mitra A, Cutrera JJ, et al. Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res 2014;74:1645–50
   PubMed Web of Science ®Google Scholar
• Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 2014;32:3483–9
   PubMed Web of Science ®Google Scholar
• Liu W, Laitinen S, Khan S, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009;15:559–65
   PubMed Web of Science ®Google Scholar
• Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209–16
   PubMed Web of Science ®Google Scholar
• Suzuki H, Freije D, Nusskern D, et al. Interfocal heterogeneity of PTEN/MMAC1gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998;58:204–9
   PubMed Web of Science ®Google Scholar
• Nagy D, Tucker E, Rajkovich S, et al. Multiplexed protein and gene profiling of circulating tumor cells (CTCs) in metastatic castration-resistant prostate cancer (mCRPC) using automated immunofluorescence and fluorescence in situ hybridization. J Clin Oncol 2013;31:abstr 158
   Google Scholar
• Leversha MA, Han J, Asgari Z, et al. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res 2009;15:2091–7
   PubMed Web of Science ®Google Scholar
• Chen CL, Mahalingam D, Osmulski P, et al. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate 2013;73:813–26
   PubMed Web of Science ®Google Scholar
• Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366–77
   PubMed Web of Science ®Google Scholar
• Ni X, Zhuo M, Su Z, et al. Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci USA 2013;110:21083–8
   PubMed Web of Science ®Google Scholar
• Smirnov DA, Zweitzig DR, Foulk BW, et al. Global gene expression profiling of circulating tumor cells. Cancer Res 2005;65:4993–7
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Li J, Beaver J, et al. Genomic analysis of circulating tumor cells (CTCs) from men with metastatic castration resistant prostate cancer (mCRPC) in the context of enzalutamide therapy. ASCO Annual Meeting Abstracts. J Clin Oncol 2014;32:abstr 65
   Web of Science ®Google Scholar
• Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013;339:580–4
   PubMed Web of Science ®Google Scholar
• Cann GM, Gulzar ZG, Cooper S, et al. mRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer. PLoS One 2012;7:e49144
   PubMed Web of Science ®Google Scholar
• Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111–15
   PubMed Web of Science ®Google Scholar
• Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821–8
   PubMed Web of Science ®Google Scholar
• Stewart JM, Shaw PA, Gedye C, et al. Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci USA 2011;108:6468–73
   PubMed Web of Science ®Google Scholar
• Chaffe CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011;331:1559–64
   PubMed Web of Science ®Google Scholar
• Zhang L, Ridgway LD, Wetzel MD, et al. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med 2013;5:180ra48
   PubMed Web of Science ®Google Scholar
• Yu M, Bardia A, Aceto N, et al. Cancer therapy: ex vivo culture of circulating breast tumor cells for individualized testing of drug. Science 2014;345:216–20
   PubMed Web of Science ®Google Scholar
• Gao D, Vela I, Sboner A, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 2014;159:176–87
   PubMed Web of Science ®Google Scholar
• Edelman GM, Gallin WJ, Delouvée A, et al. Early epochal maps of two different cell adhesion molecules. Proc Natl Acad Sci USA 1983;80:4384–8
   PubMed Web of Science ®Google Scholar
• Kim KK, Kugler MC, Wolters PJ, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 2006;103:13180–5
   PubMed Web of Science ®Google Scholar
• Scheel C, Weinberg RA. Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? Int J Cancer 2011;129:2310–14
   PubMed Web of Science ®Google Scholar
• Bitting RL, Schaeffer D, Somarelli JA, et al. The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. Cancer Metastasis Rev 2014;33:441–68
   PubMed Web of Science ®Google Scholar
• Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 2007;13:7003–11
   PubMed Web of Science ®Google Scholar
• Hance MW, Dole K, Gopal U, et al. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. J Biol Chem 2012;287:37732–44
   PubMed Web of Science ®Google Scholar
• Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 2009;119:1417–19
   PubMed Web of Science ®Google Scholar
• Lee KW, Kim JH, Han S, et al. Twist1 is an independent prognostic factor of esophageal squamous cell carcinoma and associated with its epithelial-mesenchymal transition. Ann Surg Oncol 2012;19:326–35
   Google Scholar
• Soltermann A, Tischler V, Arbogast S, et al. Prognostic significance of epithelial–mesenchymal and mesenchymal–epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res 2008;14:7430–7
   PubMed Web of Science ®Google Scholar
• Tanaka H, Kono E, Tran CP, et al. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med 2010;16:1414–20
   PubMed Web of Science ®Google Scholar
• Kallergi G, Papadaki MA, Politaki E, et al. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer 2011;13:R59
   Web of Science ®Google Scholar
• Hou JM, Krebs MG, Lancashire L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012;30:525–32
   PubMed Web of Science ®Google Scholar
• Lecharpentier A, Vielh P, Perez-Moreno P, et al. Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br J Cancer 2011;105:1338–41
   PubMed Web of Science ®Google Scholar
• Balasubramanian P, Lang JC, Jatana KR, et al. Multiparameter analysis, including EMT markers, on negatively enriched blood samples from patients with squamous cell carcinoma of the head and neck. PLoS One 2012;7:e42048
   PubMed Web of Science ®Google Scholar
• Aktas B, Tewes M, Fehm T, et al. 2009. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009;11:R46
   PubMed Web of Science ®Google Scholar
• Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009;138:645–59
   PubMed Web of Science ®Google Scholar
• Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:3213–21
   PubMed Web of Science ®Google Scholar
• Cristofanilli M. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781–91
   PubMed Web of Science ®Google Scholar
• Gazzaniga P, Gradilone A, de Berardinis E, et al. Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis. Ann Oncol 2012;23:2352–6
   PubMed Web of Science ®Google Scholar
• Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 2011;29:1556–63
   PubMed Web of Science ®Google Scholar
• Danila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 2011;17:3903–12
   PubMed Web of Science ®Google Scholar
• Scher HI, Jia X, de Bono JS, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009;10:233–9
   PubMed Web of Science ®Google Scholar
• Goldkorn A, Ely B, Quinn DI, et al. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 2014;32:1136–42
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Lee C, et al. Circulating tumor cells (CTCs) and LDH as prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing during or following docetaxel treated in the orteronel phase 3 ELM-PC 5 trial. J Clin Oncol 2014;32:5s ( suppl; abstr 5014)
   PubMed Web of Science ®Google Scholar
• Ilie M, Long E, Butori C, et al. ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. Ann Oncol 2012;23:2907–13
   PubMed Web of Science ®Google Scholar
• Pailler E, Adam J, Barthélémy A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol 2013;31:2273–81
   PubMed Web of Science ®Google Scholar
• Ware KE, Garcia-Blanco MA, Armstrong AJ, Dehm SM. Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocr Relat Cancer 2014;21:T87–103
   PubMed Web of Science ®Google Scholar
• Korpal M, Korn JM, Gao X, et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov 2013;9:1030–43
   Web of Science ®Google Scholar
• Sweeney C, Chen Y, Carducci MA, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial. J Clin Oncol 2014;32:5s ( suppl; abstr LBA2)
   PubMed Web of Science ®Google Scholar
• Beltran H, Tagawa ST, Park K, et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol 2012;30:e386–9
   PubMed Web of Science ®Google Scholar
• Mosquera JM, Beltran H, Park K, et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 2013;15:1–10
   PubMed Web of Science ®Google Scholar
• Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 1999;282:790–5
   PubMed Web of Science ®Google Scholar
• Scher HI, Heller G, Molina A, et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J Clin Oncol 2011;29:293s, abstr LBA45
   Google Scholar
• Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011;11:426–37
   PubMed Web of Science ®Google Scholar
• Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker – a critical appraisal of the literature. Clin Chim Acta 2010;411:1611–24
   PubMed Web of Science ®Google Scholar
• Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 2014;4:650–61
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H, Alix-Panabieres C, Müller I, et al. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 2009;15:1032–8
   PubMed Web of Science ®Google Scholar
• Ellinger J, Müller SC, Stadler TC, et al. The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. Urol Oncol 2011;29:124–9
   PubMed Web of Science ®Google Scholar
• Carreira S, Romanel A, Goodall J, et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med 2014;6:254ra125
   PubMed Web of Science ®Google Scholar